ClinicalTrials.gg
CompletedNCT06649045ATTAIN-OSAUpdated Sep 14, 2026

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

A Phase 3 interventional study of Orforglipron and Placebo in OSA and Overweight or Obesity, sponsored by Eli Lilly and Company. Completed at 66 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
712
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
7th of 22
712 · median 324
Started
2024
with 5 others
Phase 3
14 of 22
3 open now
Registered
12th of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 7th largest by enrollment, is one of 6 that started in 2024, is one of 14 in phase 3, and was the 12th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.

03

Conditions studied

  • OSA
  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 712 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Master GZRA inclusion criteria

  • have AHI ≥15 on PSG as part of the trial at screening (V1).
  • have (BMI) ≥27 kg/m²

Study 1 GZ01 inclusion criteria

  • Participants who are unable or unwilling to use PAP therapy.
  • Participants must not have used PAP for at least 4 weeks prior to screening.

Study 2 GZ02 inclusion criteria

  • Participants who have been on PAP therapy for at least 3 consecutive months prior to study start and plan to continue PAP therapy during the study.

Exclusion criteria

Exclusion Criteria:

Master GZRA exclusion criteria

  • Have Type 1 diabetes (T1D) or Type 2 diabetes (T2D), history of ketoacidosis, or hyperosmolar state/coma
  • Have ≥6.5% (≥ 48 mmol/mol), as determined by the central laboratory at Visit 1.
  • Had any previous or planned upper airway surgery for sleep apnea or major ear, nose or throat surgery
  • Have diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration
  • Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia.
  • Active device treatment of OSA other than PAP therapy
  • Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator.
  • Have a self-reported change in body weight >5 kg within 3 months prior to screening
  • Have a prior or planned surgical treatment for obesity (excluding liposuction, abdominoplasty or cryolipolysis if performed more than 1 year prior to screening)
  • Have a prior or planned endoscopic and/or present device-based therapy for obesity.
  • Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.

Study 2 GZ02 exclusion criteria

  • Have personal or job-related responsibilities, or in the opinion of the investigator have any situation that would make it unsafe to stop PAP therapy for 7 days prior to PSG testing during the study.
  • Are unwilling to temporary discontinue PAP therapy for 7 days prior to PSG testing during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
712 participants (actual)

Study arms

  • Experimental
    Orforglipron

    Participants will receive orforglipron orally. Study 1 GZ01: Participants who are unable or unwilling to use PAP Study 2 GZ02: Participants who plan to continue PAP therapy

    Drug: Orforglipron

  • Placebo comparator
    Placebo

    Participants will receive placebo orally. Study 1 GZ01: Participants who are unable or unwilling to use PAP Study 2 GZ02: Participants who plan to continue PAP therapy

    Drug: Placebo

Interventions

  • Administered orally.

    Also known as: LY3502970

  • DrugPlacebo

    Administered orally.

07

What researchers measure

Primary outcomes

  1. Change from Baseline in Apnea-Hypopnea Index (AHI)

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Percent Change from Baseline in AHI

    Time frame: Baseline to Week 52

  2. Change from Baseline in Sleep Apnea-Specific Hypoxic Burden (SASHB) (% min/hour)

    Time frame: Baseline to Week 52

  3. Change from Baseline in Patient-Reported Outcome Measurement Information System (PROMIS) Short Form Sleep-Related Impairment 8a T-score

    Time frame: Baseline to Week 52

  4. Percentage of Participants Achieving ≥50% AHI Reduction

    Time frame: Baseline to Week 52

  5. Percent of Participants with AHI<5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10

    Time frame: Baseline to Week 52

  6. Percent Change from Baseline in Body Weight

    Time frame: Baseline to Week 52

  7. Change from Baseline in high-sensitivity C reactive protein (hsCRP) Concentration

    Time frame: Baseline to Week 52

08

Study locations

66 sites
  • Ark Clinical Research
    Long Beach, California 90815, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Care Access - Aurora
    Aurora, Colorado 80012, United States
  • EBGS Clinical Research Center
    Snellville, Georgia 30078, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Care Access - Shreveport
    Shreveport, Louisiana 71105, United States
  • The Sleep Spot - Maimonides
    Albuquerque, New Mexico 87107, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
    Pittsburgh, Pennsylvania 15236, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Prime Revival Research Institute, LLC
    Flower Mound, Texas 75028, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Centro de Investigaciones Metabólicas (CINME)
    Buenos Aires, C1056ABI, Argentina
  • Centro Médico Viamonte
    Buenos Aires, C1120AAC, Argentina
  • Consultorio de Investigación Clínica EMO SRL
    Buenos Aires, C1405BUB, Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Buenos Aires, C1425AGC, Argentina
  • Centro Privado de Medicina Respiratoria
    Paraná, 3100, Argentina
  • Instituto Médico Río Cuarto
    Río Cuarto, X5800AEV, Argentina
  • INECO Neurociencias Oroño
    Rosario, 2000, Argentina
  • Centro de Salud e Investigaciones Médicas
    Santa Rosa, L6300, Argentina
  • Núcleo de Pesquisa Clínica do Rio Grande do Sul
    Porto Alegre, 90430-001, Brazil
  • CPQuali Pesquisa Clínica
    São Paulo, 01228-000, Brazil
  • BR Trials - Ensaios Clinicos e Consultoria
    São Paulo, 01236030, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, 04266-010, Brazil
  • Hospital das Clinicas FMUSP
    São Paulo, 05403-000, Brazil
  • Peking University People's Hospital
    Beijing, 100034, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • Sichuan Provincial People's Hospital
    Chengdu, 610072, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, 150001, China
  • Huzhou Central Hospital
    Huzhou, 313000, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang Shi, 471003, China
  • Jiangxi Provincial People's Hospital
    Nanchang, 330006, China
  • Ningbo First Hospital
    Ningbo, 315010, China
  • Pudong New Area People's Hospital Shanghai
    Shanghai, 201200, China
  • ShenZhen People's Hospital
    Shenzhen, 518020, China
  • Wuxi People's Hospital
    Wuxi, 214023, China
  • Nemocnice Rudolfa a Stefanie Benešov
    Benešov, 256 01, Czechia
  • Milan Kvapil s.r.o., Diabetologicka ambulance
    Prague, 14900, Czechia
  • Praglandia s.r.o
    Prague, 150 00, Czechia
  • CIMS Studienzentrum Bamberg
    Bamberg, 96049, Germany
  • Advanced Sleep Research
    Berlin, 10117, Germany
  • InnoDiab Forschung Gmbh
    Essen, 45136, Germany
  • Unterfrintroper Hausarztzentrum Klinische Forschung
    Essen, 45359, Germany
  • Siteworks GmbH - Hannover
    Hanover, 30449, Germany
  • Siteworks - Karlsruhe
    Karlsruhe, 76137, Germany
  • Institut für Diabetesforschung GmbH Münster
    Münster, 48145, Germany
  • RED-Institut GmbH
    Oldenburg, 23758, Germany
  • Kirigaokatsuda Hospital
    Kitakyushu, 802-0052, Japan
  • Osaka Kaisei Hospital
    Osaka, 532-0003, Japan
  • Sakai City Medical Center
    Sakai, 593-8304, Japan
  • Nakamura Clinic
    Urasoe, 901-2132, Japan
  • RESM Respiratory and Sleep Medical Care Clinic
    Yokohama, 222-0033, Japan
  • Enclifar Ensayos Clínicos Farmacológicos Sc
    Chihuahua City, 31110, Mexico
  • Diseno y Planeacion en Investigacion Medica
    Guadalajara, 44130, Mexico
  • Private Practice - Dr. Arechavaleta Granell Maria del Rosario
    Guadalajara, 44670, Mexico
  • Centro de Investigacion en Artritis y Osteoporosis SC
    Mexicali, 21200, Mexico
  • RM Pharma Specialists - Unidad Especializada en Datos
    Mexico City, 03100, Mexico
  • Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
    Mexico City, 11650, Mexico
  • CEINV Salud
    Monterrey, 64020, Mexico
  • Chiayi Christian Hospital
    Chiayi City, 600, Taiwan
  • China Medical University Hospital
    Taichung, 404332, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Malhotra A, Gottlieb DJ, Kundel V, Woehrle H, Chakladar S, Firmino Goncalves L, Calamai G. Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial. Contemp Clin Trials Commun. 2026 Jun 19;52:101660. doi: 10.1016/j.conctc.2026.101660. eCollection 2026 Aug. PubMed 42383207 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jul 2026, 20 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 20 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Oct 18, 2024
StartActual
Oct 22, 2024
Primary completionActual
Jul 21, 2026
CompletionActual
Jul 30, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06649045
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Oct 22, 2024
Primary completion
Jul 21, 2026
Completion
Jul 30, 2026
Last update
Sep 14, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion